Full-Time

Associate Statistical Geneticist/Statistical Geneticist

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$135k - $200kAnnually

+ Performance Bonus + Equity

Entry, Junior

Remote in USA

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Python
R
Data Structures & Algorithms
AWS
Linux/Unix
Data Analysis
Requirements
  • PhD in Statistical Genetics, Human Genetics, Computational Biology, or related disciplines with 0-2 years of industry or postdoctoral experience
  • Extensive experience with QC, analysis, and interpretation of human genetics data (single variant and gene-based association analysis using WES/WGS/array genotyping data)
  • Basic understanding of the architecture and analytics of EHR data from the UK Biobank or other resources (e.g., All of Us, Genomics England). Hands-on experience is strongly preferred
  • Familiarity with databases that house genomics data (including but not limited to UK Biobank, All of Us, Genomics England, gnomAD, 1000 Genomes, and TOPMed). Hands-on experience is strongly preferred
  • Proficiency in at least one major programming language (ideally Python or R)
  • Working knowledge of Unix/Linux and cloud computing (AWS) environment
  • Outstanding written and verbal communication skills in conveying analysis results to both experts and non-experts in the field
  • Proven record of success by publications in peer-reviewed journals and/or conference presentations
Responsibilities
  • Design, execute, and interpret genetics studies using diverse quantitative and binary traits from large-scale cohorts to drive the development of internal programs and external opportunities through asset acquisition
  • Integrative analysis of genetic and EHR data to support the discovery and validation of targets/biomarkers for clinical development
  • Communication of discoveries to internal teams with a variety of backgrounds (including but not limited to biologists, statisticians, physicians, and specialists in business development & asset acquisition) and to the broader scientific community through presentations and publications
  • Stay at the leading edge of human genetics (state-of-the-art algorithms/methods/tools and data resources) and be able to discuss these new developments with both experts and non-experts
Desired Qualifications
  • Experience with population stratification, Mendelian randomization, polygenic risk score (PRS) analysis, and/or gene-environment interaction analysis is strongly preferred
  • Experience with biomarker discovery
  • Experience in rare disease research
  • Basic understanding of multi-omics data (transcriptomic, proteomic, epigenomic, chromatin accessibility, etc). Hands-on experience is strongly preferred
  • Experience with analysis of imaging data (e.g., MRI, IHC)
  • Knowledge of relational databases (SQL, Postgres, etc.) and experience extracting information from such databases
  • Version control with git, which includes using branches locally, setting up and managing remote repositories, collaborating on a remote repository, working with protected branches, and submitting and resolving merge requests

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on therapies for specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to reduce the time it takes to bring treatments to market. The company promotes a culture of independent thinking and transparency, which supports quick, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off